• When Context Changes What γH2AX Means

  2026-10-15

  A γH2AX signal is informative only in relation to the biological model, treatment comparison, timing, and complementary outcomes that produced it. The reported EGCG-nanoparticle and FLASH-radiotherapy study illustrates how a stronger DNA-damage signal can support a radiosensitization hypothesis without, by itself, establishing durable double-strand-break burden, therapeutic benefit, or clinical applicability.

• BV6: Evidence Boundaries for an IAP Antagonist

  2026-10-15

  The APExBIO product description identifies BV6 as a Smac-mimetic IAP antagonist associated with apoptosis-related signaling, radiosensitization, and disease-model research. Because no identity-matched research paper is available here, the reported IC50, cellular effects, and mouse-model findings should be treated as supplier-attributed claims whose applicability, quantitative strength, and mechanistic specificity remain limited.

• PAD4-IN-2 TFA: Evidence and Scope

  2026-10-14

  PAD4-IN-2 TFA, also called Compound 5i TFA, is presented by APExBIO as a meta-phenylboronic acid–modified PAD4 inhibitor with reported effects on H3 citrullination, NET formation, tumor phenotypes and immune composition. Because no identity-matched primary paper is available in the cited material, these findings should be treated as product-description claims rather than independently verified research evidence.

• G4–STAT1 Biology and Olaparib Synergy

  2026-10-14

  A 2026 Nucleic Acids Research study reports that a G-quadruplex in the BLM promoter can recruit phosphorylated STAT1 and that berberine or coptisine may disrupt this interaction. In colon cancer models, the compounds were reported to enhance olaparib-associated cancer-cell death, but the evidence remains preclinical and does not establish clinical efficacy or applicability beyond the studied systems.

• CLCC1 and Herpesvirus Nuclear Egress

  2026-10-13

  A 2024 bioRxiv preprint identifies CLCC1 as a host factor associated with the membrane-fusion stage of HSV-1 nuclear egress. The findings support a role for CLCC1 in nuclear-envelope biology, but the study does not test Isoprinosine, establish a direct molecular mechanism, or demonstrate clinical relevance.

• Entinostat (MS-275) and Axolotl Regeneration

  2026-10-13

  A 2019 axolotl study links nerve-dependent HDAC1 expression with blastema formation and limb regeneration, while pharmacological inhibition with MS-275 delays or suppresses regeneration. The findings support an epigenetic role in regenerative biology but do not establish HDAC1 as the sole target, demonstrate applicability to humans, or provide evidence for clinical regeneration therapies.

• γH2AX and FLASH-RT: What the Evidence Shows

  2026-10-12

  A source-grounded review of a preclinical study linking EGCG nanoparticles with FLASH radiotherapy, with emphasis on γ-H2AX as a DNA-damage biomarker, immune readouts, evidence strength, and limits on clinical interpretation.

• DOT1L, Innate Immunity and Lenalidomide in Myeloma

  2026-10-12

  A 2025 Cancer Letters study links DOT1L inhibition to STING-associated innate immune signaling and reports enhanced lenalidomide responses in multiple myeloma models, while remaining preclinical and mechanistically focused.

• GKT137831: Redox Biology Beyond ROS Suppression

  2026-10-10

  GKT137831 offers a translational lens on how Nox1/Nox4-driven oxidative signaling may intersect with ferroptosis, membrane integrity, vascular remodeling, and fibrosis. This evidence-led perspective distinguishes established preclinical findings from forward-looking hypotheses and outlines where dual NADPH oxidase inhibition may add value beyond conventional ROS measurement.

• 7-dehydro Cholesterol and Causal Inference

  2026-10-09

  7-dehydro Cholesterol is more than a vitamin D3 precursor: it is a useful lens for interpreting DHCR7, sterol flux, oxidative stress, and immune phenotypes. This article examines what recent grass carp evidence establishes, what it does not prove, and how C3922 can support cross-disciplinary research without overstating causality.

• Lenalidomide (CC-5013): Evidence and Mechanism

  2026-10-09

  Lenalidomide, also called CC-5013, is an immunomodulatory drug studied in multiple myeloma and other hematologic malignancies. Recent evidence indicates that DOT1L inhibition can enhance lenalidomide-associated anti-myeloma activity through innate immune signaling, but the finding remains preclinical and model-dependent.

• Isoprinosine: Evidence, Mechanisms, and Limits

  2026-10-08

  Isoprinosine, or inosine pranobex, is described as an immunomodulatory agent for viral infections, but the supplied evidence varies substantially in provenance and detail. This overview separates supplier-reported claims from findings in a 2024 herpesvirus preprint, explains why CLCC1 biology does not establish an Isoprinosine mechanism, and outlines research applications, evidence gaps, and applicability boundaries.

• In Vitro Drug Response Analysis in Cancer

  2026-10-08

  Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability measure related but distinct components of anticancer drug response. Its central contribution is a framework for separating growth inhibition from cell killing, improving interpretation of in vitro studies without treating a single viability value as a complete mechanistic explanation.

• DOT1L, STING, and Lenalidomide in Myeloma

  2026-10-07

  A 2025 Cancer Letters study identifies DOT1L as a preferential epigenetic dependency in multiple myeloma and links its inhibition to DNA damage-associated STING signaling, type I interferon responses, and HLA class II induction. The findings provide a mechanistic rationale for combining DOT1L inhibition with lenalidomide, while remaining preclinical and requiring validation beyond the reported models.

• Ridaforolimus and Senescence Research: Evidence Review

  2026-10-07

  Ridaforolimus, also called Deforolimus or MK-8669, is a research compound described as a selective mTOR inhibitor with reported antiproliferative and anti-angiogenic activity. This overview compares those supplier-reported findings with the published machine-learning senolytic study by Smer-Barreto and colleagues, emphasizing what is established, what remains hypothetical, and where the evidence cannot support broader conclusions.

8504 records 1/567 page Next 12345 下5页 Last page